| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Analysts' ratings for Genmab (NASDAQ:GMAB) over the last quarter vary from bullish to bearish, as provided by 10 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 9 | 0 | 0 | 1 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 0 | 0 | 0 | 0 |
| 3M Ago | 3 | 0 | 0 | 1 | 0 |
Analysts have set 12-month price targets for Genmab, revealing an average target of $48.5, a high estimate of $53.00, and a low estimate of $32.00. This current average reflects an increase of 1.04% from the previous average price target of $48.00.
The perception of Genmab by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $50.00 | $50.00 |
| Asthika Goonewardene | Truist Securities | Raises | Buy | $53.00 | $50.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $50.00 | $50.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $50.00 | $50.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $50.00 | $50.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $50.00 | $50.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $50.00 | - |
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $50.00 | $50.00 |
| Matthew Harrison | Morgan Stanley | Maintains | Underweight | $32.00 | $32.00 |
| Asthika Goonewardene | Truist Securities | Maintains | Buy | $50.00 | $50.00 |
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Genmab's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Genmab analyst ratings.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Genmab showcased positive performance, achieving a revenue growth rate of 46.19% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Genmab's net margin is impressive, surpassing industry averages. With a net margin of 31.98%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.13%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Genmab's ROA excels beyond industry benchmarks, reaching 3.68%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.03.
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: GMAB
